| 1 | Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7 | 6.8 | 20 | Citations (PDF) |
| 2 | Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients | 6.8 | 27 | Citations (PDF) |
| 3 | p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane | 5.5 | 2 | Citations (PDF) |
| 4 | Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer | 5.3 | 21 | Citations (PDF) |
| 5 | Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer | 27.4 | 89 | Citations (PDF) |
| 6 | Cancer biomarkers: Emerging trends and clinical implications for personalized treatmentCell, 2024, 187, 1617-1635 | 33.6 | 562 | Citations (PDF) |
| 7 | Efficacy and Safety of Immune Checkpoint Blockade in Patients With Li-Fraumeni Syndrome | 1.9 | 5 | Citations (PDF) |
| 8 | Sopa: a technology-invariant pipeline for analyses of image-based spatial omics | 13.7 | 45 | Citations (PDF) |
| 9 | Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors | 5.5 | 9 | Citations (PDF) |
| 10 | Metabolomic Prediction of Breast Cancer Treatment–Induced Neurologic and Metabolic Toxicities | 6.8 | 8 | Citations (PDF) |
| 11 | Understanding and Overcoming Resistance to Selective FGFR Inhibitors across
FGFR2
-Driven Malignancies | 6.8 | 38 | Citations (PDF) |
| 12 | The genomic and transcriptomic landscape of metastastic urothelial cancer | 13.7 | 19 | Citations (PDF) |
| 13 | A benchmarking study of individual somatic variant callers and voting-based ensembles for whole-exome sequencing | 6.6 | 8 | Citations (PDF) |
| 14 | Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor–Positive Breast Cancers | 6.8 | 7 | Citations (PDF) |
| 15 | Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer | 25.1 | 51 | Citations (PDF) |
| 16 | SA 1.4 Translational research priorities for patients with early breast cancer | 2.3 | 0 | Citations (PDF) |
| 17 | Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors | 6.8 | 14 | Citations (PDF) |
| 18 | Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors | 6.8 | 22 | Citations (PDF) |
| 19 | Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial | 33.0 | 349 | Citations (PDF) |
| 20 | A biology-driven deep generative model for cell-type annotation in cytometry | 6.6 | 7 | Citations (PDF) |
| 21 | Precision medicine in the era of multi-omics: can the data tsunami guide rational treatment decision? | 5.3 | 39 | Citations (PDF) |
| 22 | Can Precision Oncology Benefit Patients With Cancers of Unknown Primary? | 3.4 | 4 | Citations (PDF) |
| 23 | Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review | 9.9 | 75 | Citations (PDF) |
| 24 | Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score | 6.8 | 80 | Citations (PDF) |
| 25 | A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer | 9.9 | 51 | Citations (PDF) |
| 26 | Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer | 6.4 | 71 | Citations (PDF) |
| 27 | The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals | 25.1 | 16 | Citations (PDF) |
| 28 | Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 | 1.9 | 41 | Citations (PDF) |
| 29 | Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | 34.5 | 725 | Citations (PDF) |
| 30 | Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management | 9.5 | 165 | Citations (PDF) |
| 31 | Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion | 16.9 | 258 | Citations (PDF) |
| 32 | Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France | 6.6 | 46 | Citations (PDF) |
| 33 | Real-Time Detection of ESR1 Mutation in Blood by Droplet Digital PCR in the PADA-1 Trial: Feasibility and Cross-Validation with NGS | 6.5 | 25 | Citations (PDF) |
| 34 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update | 16.9 | 335 | Citations (PDF) |
| 35 | Natural History and Characteristics of
ERBB2
-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE | 6.8 | 3 | Citations (PDF) |
| 36 | Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study | 6.8 | 190 | Citations (PDF) |
| 37 | Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients | 9.7 | 17 | Citations (PDF) |
| 38 | Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A | 2.9 | 5 | Citations (PDF) |
| 39 | Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study | 5.5 | 12 | Citations (PDF) |
| 40 | Escherichia coli
–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer | 25.1 | 72 | Citations (PDF) |
| 41 | PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials | 2.9 | 66 | Citations (PDF) |
| 42 | Genomics to select treatment for patients with metastatic breast cancer | 37.9 | 153 | Citations (PDF) |
| 43 | Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis | 25.1 | 96 | Citations (PDF) |
| 44 | Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer | 14.3 | 117 | Citations (PDF) |
| 45 | Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions | 6.6 | 8 | Citations (PDF) |
| 46 | Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care | 1.9 | 55 | Citations (PDF) |
| 47 | Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer | 4.6 | 101 | Citations (PDF) |
| 48 | Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub‐study of the French CANTO cohort | 3.0 | 10 | Citations (PDF) |
| 49 | A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency | 25.1 | 48 | Citations (PDF) |
| 50 | AI-driven quantification, staging and outcome prediction of COVID-19 pneumonia | 10.6 | 144 | Citations (PDF) |
| 51 | Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1 | 9.9 | 542 | Citations (PDF) |
| 52 | ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research | 9.9 | 118 | Citations (PDF) |
| 53 | Genomic Alterations in
PIK3CA
-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors | 3.8 | 35 | Citations (PDF) |
| 54 | Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers | 8.5 | 160 | Citations (PDF) |
| 55 | Tribbles Pseudokinase 3 Regulation and Contribution to Cancer | 3.8 | 34 | Citations (PDF) |
| 56 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial | 27.4 | 435 | Citations (PDF) |
| 57 | Why does endocrine therapy work and why does it stop working | 2.3 | 0 | Citations (PDF) |
| 58 | Unhealthy behaviors after breast cancer: Capitalizing on a teachable moment to promote lifestyle improvements | 4.0 | 33 | Citations (PDF) |
| 59 | Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies | 25.1 | 272 | Citations (PDF) |
| 60 | Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial | 9.6 | 45 | Citations (PDF) |
| 61 | Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment | 13.3 | 147 | Citations (PDF) |
| 62 | Multifaceted modes of action of the anticancer probiotic Enterococcus hirae | 13.3 | 49 | Citations (PDF) |
| 63 | PI3K inhibitors are finally coming of age | 79.7 | 428 | Citations (PDF) |
| 64 | Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer | 2.3 | 3 | Citations (PDF) |
| 65 | Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index | 8.5 | 37 | Citations (PDF) |
| 66 | Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis | 13.3 | 37 | Citations (PDF) |
| 67 | Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study | 4.9 | 25 | Citations (PDF) |
| 68 | Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue | 2.3 | 15 | Citations (PDF) |
| 69 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 | 9.9 | 708 | Citations (PDF) |
| 70 | Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial | 33.0 | 148 | Citations (PDF) |
| 71 | Immunodynamics of explanted human tumors for immuno‐oncology | 7.1 | 10 | Citations (PDF) |
| 72 | Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates | 14.3 | 149 | Citations (PDF) |
| 73 | A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial) | 4.9 | 12 | Citations (PDF) |
| 74 | Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation | 4.9 | 43 | Citations (PDF) |
| 75 | L’intelligence artificielle pourrait-elle intervenir dans l’aide au diagnostic des cancers du sein ? – L’exemple de HER2 | 0.6 | 4 | Citations (PDF) |
| 76 | Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer | 6.8 | 158 | Citations (PDF) |
| 77 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | 34.5 | 1,802 | Citations (PDF) |
| 78 | Prediction of Breast Cancer Treatment–Induced Fatigue by Machine Learning Using Genome-Wide Association Data | 2.9 | 21 | Citations (PDF) |
| 79 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) | 9.9 | 1,217 | Citations (PDF) |
| 80 | Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group | 9.9 | 1,058 | Citations (PDF) |
| 81 | Progresses Toward Precision Medicine inRET-altered Solid Tumors | 6.8 | 57 | Citations (PDF) |
| 82 | Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation | 6.3 | 151 | Citations (PDF) |
| 83 | Body weight and return to work among survivors of early-stage breast cancer | 5.3 | 18 | Citations (PDF) |
| 84 | Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer | 13.7 | 114 | Citations (PDF) |
| 85 | Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19Cell, 2020, 182, 1401-1418.e18 | 33.6 | 813 | Citations (PDF) |
| 86 | Pervasive chromosomal instability and karyotype order in tumour evolution | 37.9 | 347 | Citations (PDF) |
| 87 | Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort | 22.5 | 111 | Citations (PDF) |
| 88 | Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy | 6.5 | 26 | Citations (PDF) |
| 89 | Immune responses during COVID-19 infection | 5.4 | 126 | Citations (PDF) |
| 90 | Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage | 36.3 | 362 | Citations (PDF) |
| 91 | Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer | 9.9 | 178 | Citations (PDF) |
| 92 | Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials | 6.4 | 20 | Citations (PDF) |
| 93 | Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer | 4.9 | 89 | Citations (PDF) |
| 94 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | 6.4 | 173 | Citations (PDF) |
| 95 | The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers | 3.8 | 11 | Citations (PDF) |
| 96 | Rapalog-Mediated Repression of Tribbles Pseudokinase 3 Regulates Pre-mRNA Splicing | 3.8 | 6 | Citations (PDF) |
| 97 | Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future | 62.1 | 428 | Citations (PDF) |
| 98 | Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort Subgroup | 1.1 | 31 | Citations (PDF) |
| 99 | Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer | 9.9 | 282 | Citations (PDF) |
| 100 | Characteristics and Outcome of
AKT1
E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry | 25.1 | 50 | Citations (PDF) |
| 101 | A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer | 4.9 | 26 | Citations (PDF) |
| 102 | HER2-Low Breast Cancer: Pathological and Clinical Landscape | 16.9 | 698 | Citations (PDF) |
| 103 | Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial | 27.4 | 231 | Citations (PDF) |
| 104 | Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study | 2.3 | 24 | Citations (PDF) |
| 105 | Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study | 6.8 | 56 | Citations (PDF) |
| 106 | TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer | 2.3 | 115 | Citations (PDF) |
| 107 | Ribosomal RNA 2′O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer | 2.8 | 75 | Citations (PDF) |
| 108 | Genomic Alteration in Metastatic Breast Cancer and Its Treatment | 4.4 | 116 | Citations (PDF) |
| 109 | ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research | 9.9 | 338 | Citations (PDF) |
| 110 | Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis | 9.9 | 209 | Citations (PDF) |
| 111 | Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy | 7.5 | 43 | Citations (PDF) |
| 112 | Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis | 1.1 | 81 | Citations (PDF) |
| 113 | A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer | 2.1 | 19 | Citations (PDF) |
| 114 | Outcome and mutational landscape of patients with PIK3CA-mutated metastatic breast cancer (mBC) | 9.9 | 8 | Citations (PDF) |
| 115 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx | 16.9 | 214 | Citations (PDF) |
| 116 | 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial | 62.1 | 130 | Citations (PDF) |
| 117 | Genomic characterization of metastatic breast cancers | 37.9 | 617 | Citations (PDF) |
| 118 | Alpelisib for
PIK3CA
-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | 34.5 | 2,437 | Citations (PDF) |
| 119 | Impassion132 Phase Iii Trial: Atezolizumab And Chemotherapy In Early Relapsing Metastatic Triple-Negative Breast Cancer | 2.3 | 65 | Citations (PDF) |
| 120 | ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach | 9.9 | 953 | Citations (PDF) |
| 121 | Fatigue and physical activity in cancer survivors: A cross‐sectional population‐based study | 2.6 | 42 | Citations (PDF) |
| 122 | T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants | 9.9 | 25 | Citations (PDF) |
| 123 | Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial | 27.4 | 429 | Citations (PDF) |
| 124 | Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study | 8.0 | 68 | Citations (PDF) |
| 125 | Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy | 9.9 | 216 | Citations (PDF) |
| 126 | An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells | 13.7 | 102 | Citations (PDF) |
| 127 | Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations | 1.9 | 22 | Citations (PDF) |
| 128 | Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies | 2.3 | 11 | Citations (PDF) |
| 129 | Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door | 4.9 | 18 | Citations (PDF) |
| 130 | Funding sources of practice-changing trials | 9.9 | 9 | Citations (PDF) |
| 131 | Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer | 9.9 | 348 | Citations (PDF) |
| 132 | Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al. | 9.9 | 4 | Citations (PDF) |
| 133 | The European Society for Medical Oncology (ESMO) Precision Medicine Glossary | 9.9 | 149 | Citations (PDF) |
| 134 | ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors | 6.8 | 35 | Citations (PDF) |
| 135 | A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer | 9.9 | 58 | Citations (PDF) |
| 136 | American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond—Lessons Learned and Member Institutions’ Perspectives | 2.0 | 40 | Citations (PDF) |
| 137 | TRIB3: A new transcriptional target gene of rapalogs, modulating their effects on splicing | 9.9 | 0 | Citations (PDF) |
| 138 | PO-497 Microtubule regulatory proteins as predictive biomarkers of taxane-based chemoresistance in breast cancer? | 5.3 | 0 | Citations (PDF) |
| 139 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | 34.5 | 1,142 | Citations (PDF) |
| 140 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial | 25.1 | 582 | Citations (PDF) |
| 141 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) | 9.9 | 1,054 | Citations (PDF) |
| 142 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) | 9.9 | 724 | Citations (PDF) |
| 143 | Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors | 1.8 | 20 | Citations (PDF) |
| 144 | Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial | 9.9 | 58 | Citations (PDF) |
| 145 | Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis | 2.3 | 16 | Citations (PDF) |
| 146 | Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2− breast cancer that had progressed during or after prior endocrine therapy | 4.7 | 103 | Citations (PDF) |
| 147 | Towards a global cancer knowledge network: dissecting the current international cancer genomic sequencing landscape | 9.9 | 24 | Citations (PDF) |
| 148 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) | 9.9 | 965 | Citations (PDF) |
| 149 | AACR Project GENIE: Powering Precision Medicine through an International Consortium | 25.1 | 1,819 | Citations (PDF) |
| 150 | A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers | 6.8 | 129 | Citations (PDF) |
| 151 | High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial | 25.1 | 715 | Citations (PDF) |
| 152 | Advances in the treatment of advanced oestrogen-receptor-positive breast cancer | 62.1 | 196 | Citations (PDF) |
| 153 | 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) | 2.3 | 193 | Citations (PDF) |
| 154 | Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies | 4.9 | 34 | Citations (PDF) |
| 155 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | 2.3 | 744 | Citations (PDF) |
| 156 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 2.3 | 637 | Citations (PDF) |
| 157 | Characteristics of the Metastatic Breast Cancer Population with PIK3CA Mutation in the Randomized Phase II Study SAFIR02 Breast (UCBG-0105/1304) | 2.3 | 0 | Citations (PDF) |
| 158 | Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results | 3.4 | 133 | Citations (PDF) |
| 159 | Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab | 9.9 | 66 | Citations (PDF) |
| 160 | Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients | 2.3 | 95 | Citations (PDF) |
| 161 | De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 | 9.9 | 999 | Citations (PDF) |
| 162 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update | 16.9 | 267 | Citations (PDF) |
| 163 | A Systematic Evaluation of Blood Serum and Plasma Pre-Analytics for Metabolomics Cohort Studies | 4.4 | 72 | Citations (PDF) |
| 164 | Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis | 8.0 | 353 | Citations (PDF) |
| 165 | Crizotinib-Resistant
ROS1
Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for
ROS1
- and
ALK
-Rearranged Lung Cancers | 6.8 | 144 | Citations (PDF) |
| 166 | The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy | 2.7 | 41 | Citations (PDF) |
| 167 | Consensus on precision medicine for metastatic cancers: a report from the MAP conference | 9.9 | 82 | Citations (PDF) |
| 168 | Dépistage du cancer du sein : en route vers le futur | 0.6 | 14 | Citations (PDF) |
| 169 | The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic | 4.9 | 41 | Citations (PDF) |
| 170 | Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | 34.5 | 1,853 | Citations (PDF) |
| 171 | The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ | 5.4 | 53 | Citations (PDF) |
| 172 | Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations | 3.8 | 16 | Citations (PDF) |
| 173 | Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial | 9.9 | 166 | Citations (PDF) |
| 174 | Les essais cliniques : leur apport dans le parcours de soins des patientes traitées pour un cancer du sein | 0.8 | 1 | Citations (PDF) |
| 175 | Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial | 6.8 | 107 | Citations (PDF) |
| 176 | The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer | 13.7 | 108 | Citations (PDF) |
| 177 | rCGH: a comprehensive array-based genomic profile platform for precision medicine | 4.7 | 19 | Citations (PDF) |
| 178 | Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01) | 4.9 | 46 | Citations (PDF) |
| 179 | Statistical controversies in clinical research: statistical significance—too much of a good thing … | 9.9 | 12 | Citations (PDF) |
| 180 | Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline | 16.9 | 743 | Citations (PDF) |
| 181 | Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor | 2.1 | 8 | Citations (PDF) |
| 182 | Whole exome sequencing of rare aggressive breast cancer histologies | 2.3 | 43 | Citations (PDF) |
| 183 | Dendritic cell–derived exosomes for cancer therapy | 10.6 | 594 | Citations (PDF) |
| 184 | Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive, human epidermal growth factor receptor-2–negative advanced breast cancer in Europe | 2.9 | 7 | Citations (PDF) |
| 185 | TumorTracer: a method to identify the tissue of origin from the somatic mutations of a tumor specimen | 1.7 | 57 | Citations (PDF) |
| 186 | Precision Medicine for Metastatic Breast Cancer | 4.4 | 16 | Citations (PDF) |
| 187 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer | 34.5 | 1,509 | Citations (PDF) |
| 188 | Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials | 9.9 | 286 | Citations (PDF) |
| 189 | Rationale for targeting fibroblast growth factor receptor signaling in breast cancer | 2.3 | 128 | Citations (PDF) |
| 190 | Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial | 27.4 | 296 | Citations (PDF) |
| 191 | Precision medicine for metastatic breast cancer—limitations and solutions | 70.7 | 311 | Citations (PDF) |
| 192 | Targeting FGFR Signaling in Cancer | 6.8 | 486 | Citations (PDF) |
| 193 | Les signatures moléculaires commerciales : quelle utilité clinique ? | 0.6 | 2 | Citations (PDF) |
| 194 | Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles | 4.9 | 89 | Citations (PDF) |
| 195 | Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 | 9.9 | 1,661 | Citations (PDF) |
| 196 | Impact of centralization on aCGH-based genomic profiles for precision medicine in oncology | 9.9 | 14 | Citations (PDF) |
| 197 | Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA | 2.3 | 19 | Citations (PDF) |
| 198 | Ki67—no evidence for its use in node-positive breast cancer | 70.7 | 69 | Citations (PDF) |
| 199 | Targeted therapies for ER+/HER2- metastatic breast cancer | 7.1 | 74 | Citations (PDF) |
| 200 | Natural and therapy-induced immunosurveillance in breast cancer | 33.0 | 304 | Citations (PDF) |
| 201 | EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients | 9.9 | 300 | Citations (PDF) |
| 202 | Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer | 13.7 | 101 | Citations (PDF) |
| 203 | Overcoming Implementation Challenges of Personalized Cancer Therapy in Patients with Breast Cancer | 9.9 | 0 | Citations (PDF) |
| 204 | The Horizon of Precision Medicine in Breast Cancer: Fragmentation, Alliance, or Reunification? | 4.4 | 6 | Citations (PDF) |
| 205 | Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy | 6.8 | 185 | Citations (PDF) |
| 206 | Utilisation de référentiels et hétérogénéité décisionnelle des indications de chimiothérapie adjuvante dans les cancers du sein exprimant les récepteurs hormonaux, HER2-négatifs: résultats d’un sondage national en France | 0.6 | 6 | Citations (PDF) |
| 207 | Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors | 9.9 | 165 | Citations (PDF) |
| 208 | Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer | 2.1 | 44 | Citations (PDF) |
| 209 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) | 9.9 | 425 | Citations (PDF) |
| 210 | Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution | 8.1 | 73 | Citations (PDF) |
| 211 | Genomes in the clinic: the Gustave Roussy Cancer Center experience | 3.2 | 11 | Citations (PDF) |
| 212 | Decision-making from multidisciplinary team meetings to the bedside: Factors influencing the recruitment of breast cancer patients into clinical trials | 2.3 | 8 | Citations (PDF) |
| 213 | TP53 mutation‐correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53‐mutated breast cancers | 4.1 | 64 | Citations (PDF) |
| 214 | Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | 27.4 | 464 | Citations (PDF) |
| 215 | The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? | 4.9 | 52 | Citations (PDF) |
| 216 | ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) | 2.3 | 297 | Citations (PDF) |
| 217 | Clinical development of mTOR inhibitors in breast cancer | 4.7 | 53 | Citations (PDF) |
| 218 | Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives | 4.7 | 72 | Citations (PDF) |
| 219 | Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | 33.0 | 993 | Citations (PDF) |
| 220 | Dendritic Cell–Derived Exosomes as Immunotherapies in the Fight against Cancer | 0.6 | 269 | Citations (PDF) |
| 221 | Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials | 7.1 | 72 | Citations (PDF) |
| 222 | Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community? | 9.5 | 56 | Citations (PDF) |
| 223 | Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) | 27.4 | 373 | Citations (PDF) |
| 224 | Chk1 as a new therapeutic target in triple-negative breast cancer | 2.3 | 55 | Citations (PDF) |
| 225 | Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study | 9.9 | 401 | Citations (PDF) |
| 226 | A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer | 6.5 | 97 | Citations (PDF) |
| 227 | Gene copy number variations in breast cancer of Sub-Saharan African women | 2.3 | 11 | Citations (PDF) |
| 228 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | 9.9 | 3,370 | Citations (PDF) |
| 229 | A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy | 2.3 | 73 | Citations (PDF) |
| 230 | Prolifération des cancers du sein et biomarqueurs décisionnels en pratique RPC (RPC 2013) | 0.8 | 2 | Citations (PDF) |
| 231 | Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer | 6.8 | 181 | Citations (PDF) |
| 232 | Outcome in breast molecular subtypes according to nodal status and surgical procedures | 1.7 | 46 | Citations (PDF) |
| 233 | PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs | 2.6 | 44 | Citations (PDF) |
| 234 | 19q13-ERCC1 Gene Copy Number Increase in Non–Small-Cell Lung Cancer | 2.8 | 10 | Citations (PDF) |
| 235 | Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives | 25.1 | 397 | Citations (PDF) |
| 236 | ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer | 34.5 | 365 | Citations (PDF) |
| 237 | mTOR inhibitors in advanced breast cancer: Ready for prime time? | 9.5 | 27 | Citations (PDF) |
| 238 | Retinoic Acid Receptor Alpha Amplifications and Retinoic Acid Sensitivity in Breast Cancers | 2.3 | 16 | Citations (PDF) |
| 239 | DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes | 3.4 | 81 | Citations (PDF) |
| 240 | Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer | 6.8 | 295 | Citations (PDF) |
| 241 | ATIP3, a Novel Prognostic Marker of Breast Cancer Patient Survival, Limits Cancer Cell Migration and Slows Metastatic Progression by Regulating Microtubule Dynamics | 3.8 | 63 | Citations (PDF) |
| 242 | Issues in clinical research for metastatic breast cancer | 2.1 | 8 | Citations (PDF) |
| 243 | Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement | 9.9 | 118 | Citations (PDF) |
| 244 | Targeting the Deregulated Spliceosome Core Machinery in Cancer Cells Triggers mTOR Blockade and Autophagy | 3.8 | 99 | Citations (PDF) |
| 245 | New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer | 2.1 | 13 | Citations (PDF) |
| 246 | Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology | 6.8 | 34 | Citations (PDF) |
| 247 | Reproducibility of research and preclinical validation: problems and solutions | 70.7 | 98 | Citations (PDF) |
| 248 | Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists | 13.3 | 241 | Citations (PDF) |
| 249 | Abstract CN02-02: From precision medicine to personalized medicine in metastatic breast cancer patients. 2013, , | | 0 | Citations (PDF) |
| 250 | Abstract A130: Joint cell-line (CCLE, Sanger) and patient (TCGA) modeling of drug sensitivity reveals novel molecular biomarkers for targeted therapy and conventional chemotherapy. 2013, , | | 0 | Citations (PDF) |
| 251 | Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer | 9.9 | 12 | Citations (PDF) |
| 252 | Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses | 9.9 | 62 | Citations (PDF) |
| 253 | DNA Repair Capacity in Circulating Lymphocytes and Influence on Platinum Effect in Tumor Cells | 16.9 | 3 | Citations (PDF) |
| 254 | Triple-negative breast cancer: are we making headway at least? | 3.6 | 87 | Citations (PDF) |
| 255 | A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes | 5.5 | 46 | Citations (PDF) |
| 256 | Breast Cancer Index predicts pathological complete response and eligibility for breast conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy | 9.9 | 39 | Citations (PDF) |
| 257 | Molecular biology in breast cancer: Should molecular classifiers be assessed by conventional tools or by gene expression arrays? | 5.0 | 11 | Citations (PDF) |
| 258 | Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer | 4.9 | 21 | Citations (PDF) |
| 259 | Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing | 2.3 | 5 | Citations (PDF) |
| 260 | Discrepancies between primary tumor and metastasis: A literature review on clinically established biomarkers | 5.0 | 82 | Citations (PDF) |
| 261 | The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: The case of the Institut Gustave Roussy | 4.1 | 18 | Citations (PDF) |
| 262 | Échappement tumoral aux inhibiteurs de HER2 : théorie de la sédimentation | 0.6 | 1 | Citations (PDF) |
| 263 | A Prospective Randomized Trial Evaluating Gene Expression Arrays to Select Neoadjuvant Chemotherapy Regimen for Operable Breast Cancer: First Report of the Remagus04 Trial | 9.9 | 0 | Citations (PDF) |
| 264 | Prediction of Disease Outcome With Quantitative Measurement of HER-2 Receptor Expression and Dimerization in Patients With Breast Cancer | 9.9 | 1 | Citations (PDF) |
| 265 | 119P Evolution and Landscape of Clinical Trials for Breast Cancer Patients | 9.9 | 0 | Citations (PDF) |
| 266 | Patterns of Clinical Management and Resource Utilization for Postmenopausal Hormone-Receptor–Positive HER2-Negative (HR+ HER2–) Advanced Breast Cancer (ABC) in Europe | 9.9 | 2 | Citations (PDF) |
| 267 | Significant Antitumor Activity of E-3810, a Novel FGFR and VEGFR Inhibitor, in Patients With FGFR1 Amplified Breast Cancer | 9.9 | 15 | Citations (PDF) |
| 268 | Characteristics of Patients With HER2-Positive Metastatic (MBC) or Locally Advanced Breast Cancer (ABC), Treated With Trastuzumab (T) as 1st Line-Therapy and Progression-Free for at Least 3 Years: Interim Analysis of the Lorha Study | 9.9 | 0 | Citations (PDF) |
| 269 | 9O_PR Gene Modules and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. A Pooled Analysis | 9.9 | 4 | Citations (PDF) |
| 270 | Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death | 12.5 | 423 | Citations (PDF) |
| 271 | TLR3 as a Biomarker for the Therapeutic Efficacy of Double-stranded RNA in Breast Cancer | 3.8 | 112 | Citations (PDF) |
| 272 | Le point de vue du clinicien : ciblage des kinases en pathologie mammaire | 0.2 | 0 | Citations (PDF) |
| 273 | Implications of personalized medicine—perspective from a cancer center | 70.7 | 55 | Citations (PDF) |
| 274 | Biomarker studies: a call for a comprehensive biomarker study registry | 70.7 | 114 | Citations (PDF) |
| 275 | Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues | 4.9 | 42 | Citations (PDF) |
| 276 | 801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted Agents | 4.9 | 1 | Citations (PDF) |
| 277 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial | 4.7 | 24 | Citations (PDF) |
| 278 | Her2 : un modèle de cible thérapeutique | 0.6 | 4 | Citations (PDF) |
| 279 | Resistance to HER2 inhibitors: Is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation | 5.0 | 22 | Citations (PDF) |
| 280 | Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer | 4.6 | 219 | Citations (PDF) |
| 281 | Le cancer du sein chez la femme de l’Afrique sub-saharienne : état actuel des connaissances | 0.6 | 47 | Citations (PDF) |
| 282 | Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers | 6.8 | 58 | Citations (PDF) |
| 283 | A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas | 5.5 | 387 | Citations (PDF) |
| 284 | Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC | 6.8 | 61 | Citations (PDF) |
| 285 | ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy | 9.9 | 15 | Citations (PDF) |
| 286 | Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review | 2.3 | 275 | Citations (PDF) |
| 287 | DNA Damage Repair and Telomere Length in Normal Breast, Preneoplastic Lesions, and Invasive Cancer | 1.3 | 40 | Citations (PDF) |
| 288 | Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients | 2.1 | 58 | Citations (PDF) |
| 289 | Rapport 2009 sur l’état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein | 0.8 | 2 | Citations (PDF) |
| 290 | Traitements médicaux guidés par la biologie en pathologie mammaire | 0.8 | 1 | Citations (PDF) |
| 291 | Breast Cancer Classification to Select Patients for Cancer Treatment | 0.8 | 0 | Citations (PDF) |
| 292 | Characteristics, Treatment, and Outcome of Breast Cancers Diagnosed in BRCA1 and BRCA2 Gene Mutation Carriers in Intensive Screening Programs Including Magnetic Resonance Imaging | 2.3 | 27 | Citations (PDF) |
| 293 | Expression of Chemokine Receptor CCR6 as a Molecular Determinant of Adrenal Metastatic Relapse in Patients With Primary Lung Cancer | 2.8 | 28 | Citations (PDF) |
| 294 | A nomogram to predict for malignant diagnosis of BI‐RADS category 4 breast lesions | 1.5 | 9 | Citations (PDF) |
| 295 | Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2‐positive breast cancer using an LC‐MALDI‐TOF/MS procedure | 3.1 | 20 | Citations (PDF) |
| 296 | The interferon-alpha and interleukin-10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life | 3.3 | 37 | Citations (PDF) |
| 297 | Gene expression profiling identifies Fibronectin 1 and CXCL9 as candidate biomarkers for breast cancer screening | 5.5 | 45 | Citations (PDF) |
| 298 | Molecular circuits of solid tumors: prognostic and predictive tools for bedside use | 70.7 | 96 | Citations (PDF) |
| 299 | Estrogen Receptor Expression and Docetaxel Efficacy in Patients with Metastatic Breast Cancer: A Pooled Analysis of Four Randomized Trials | 3.4 | 6 | Citations (PDF) |
| 300 | Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 Ligands | 3.8 | 108 | Citations (PDF) |
| 301 | Integration of Host-Related Signatures with Cancer Cell–Derived Predictors for the Optimal Management of Anticancer Chemotherapy | 3.8 | 29 | Citations (PDF) |
| 302 | First-generation genomic tests for breast cancer treatment | 27.4 | 12 | Citations (PDF) |
| 303 | Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets | 9.6 | 44 | Citations (PDF) |
| 304 | Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers | 3.4 | 51 | Citations (PDF) |
| 305 | Prévalence de l'élévation du CA 15-3 lors de la rechute métastatique des cancers du sein: corrélation avec l'expression des récepteurs hormonaux et de Her2 | 0.6 | 9 | Citations (PDF) |
| 306 | CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence | 3.4 | 65 | Citations (PDF) |
| 307 | Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial | 16.9 | 84 | Citations (PDF) |
| 308 | Fine‐needle aspiration for nucleic acid‐ased molecular analyses in breast cancer | 2.5 | 17 | Citations (PDF) |
| 309 | Evaluating beauty care provided by the hospital to women suffering from breast cancer: qualitative aspects | 2.2 | 33 | Citations (PDF) |
| 310 | Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors | 33.0 | 1,846 | Citations (PDF) |
| 311 | Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis | 27.4 | 56 | Citations (PDF) |
| 312 | Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate | 2.3 | 47 | Citations (PDF) |
| 313 | Traitement par le Ca-DTPA des contaminations internes par le plutonium et l’américium : Recommandations pour la rédaction de protocoles dans les centres CEA et AREVA | 1.6 | 5 | Citations (PDF) |
| 314 | Dendritic Cell-Derived Exosomes Promote Natural Killer Cell Activation and Proliferation: A Role for NKG2D Ligands and IL-15Rα | 2.3 | 418 | Citations (PDF) |
| 315 | Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers | 5.5 | 44 | Citations (PDF) |
| 316 | Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses | 3.0 | 18 | Citations (PDF) |
| 317 | Evaluation of biological pathways involved in chemotherapy response in breast cancer | 4.7 | 56 | Citations (PDF) |
| 318 | Gene expression predictors in breast cancer: Current status, limitations and perspectives | 4.9 | 54 | Citations (PDF) |
| 319 | Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer | 16.9 | 2,685 | Citations (PDF) |
| 320 | Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy | 9.9 | 15 | Citations (PDF) |
| 321 | p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes | 9.9 | 55 | Citations (PDF) |
| 322 | Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor–Positive Breast Cancer | 16.9 | 30 | Citations (PDF) |
| 323 | Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer | 9.9 | 31 | Citations (PDF) |
| 324 | Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions | 9.9 | 53 | Citations (PDF) |
| 325 | The anticancer immune response: indispensable for therapeutic success? | 10.6 | 536 | Citations (PDF) |
| 326 | Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis | 16.9 | 55 | Citations (PDF) |
| 327 | Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome | 16.9 | 272 | Citations (PDF) |
| 328 | Efficacy of adjuvant chemotherapy according to Prion protein expression in patients with estrogen receptor-negative breast cancer | 9.9 | 40 | Citations (PDF) |
| 329 | Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials | 9.9 | 76 | Citations (PDF) |
| 330 | Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers | 9.9 | 70 | Citations (PDF) |
| 331 | What can breast cancer molecular sub-classification add to conventional diagnostic tools? | 9.9 | 6 | Citations (PDF) |
| 332 | Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers | 9.9 | 69 | Citations (PDF) |
| 333 | A Study of the Immunological Response to Tumor Ablation with Irreversible Electroporation | 2.3 | 108 | Citations (PDF) |
| 334 | Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program | 16.9 | 113 | Citations (PDF) |
| 335 | Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study | 27.4 | 179 | Citations (PDF) |
| 336 | Lésions bénignes du sein et risque de transformation maligne : le point de vue de l’oncologue aujourd’hui | 0.1 | 0 | Citations (PDF) |
| 337 | Gene-Expression Biomarkers as Predictors of Recurrence and Treatment-Related Outcomes in Breast Cancer | 0.0 | 1 | Citations (PDF) |
| 338 | Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy | 4.0 | 45 | Citations (PDF) |
| 339 | Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | 33.0 | 2,929 | Citations (PDF) |
| 340 | The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy | 6.4 | 536 | Citations (PDF) |
| 341 | HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer | 2.3 | 93 | Citations (PDF) |
| 342 | 3–1 Tumor Gene Expression and Prognosis in Breast Cancer Patients With 10 or More Positive Lymph Nodes | 0.0 | 0 | Citations (PDF) |
| 343 | DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy | 34.5 | 1,664 | Citations (PDF) |
| 344 | Heterogeneity of Breast Cancer among Patients and Implications for Patient Selection for Adjuvant Chemotherapy | 3.7 | 11 | Citations (PDF) |
| 345 | Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d’une chimiothérapie adjuvante? | 0.8 | 0 | Citations (PDF) |
| 346 | DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design | 7.0 | 16 | Citations (PDF) |
| 347 | Dendritic cell derived-exosomes: biology and clinical implementations | 2.9 | 130 | Citations (PDF) |
| 348 | Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy | 6.6 | 122 | Citations (PDF) |
| 349 | Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer | 9.9 | 176 | Citations (PDF) |
| 350 | Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases | 9.9 | 91 | Citations (PDF) |
| 351 | Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer | 16.9 | 279 | Citations (PDF) |
| 352 | Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer | 16.9 | 28 | Citations (PDF) |
| 353 | The potential of exosomes in immunotherapy | 3.0 | 48 | Citations (PDF) |
| 354 | The potential of exosomes in immunotherapy of cancer | 1.6 | 43 | Citations (PDF) |
| 355 | Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC | 4.9 | 27 | Citations (PDF) |
| 356 | Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period | 16.9 | 399 | Citations (PDF) |
| 357 | Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome | 9.9 | 202 | Citations (PDF) |
| 358 | Exosomes as Potent Cell-Free Peptide-Based Vaccine. I. Dendritic Cell-Derived Exosomes Transfer Functional MHC Class I/Peptide Complexes to Dendritic Cells | 0.6 | 470 | Citations (PDF) |
| 359 | Risk factors for brain relapse in patients with metastatic breast cancer | 9.9 | 151 | Citations (PDF) |
| 360 | Exosomes for cancer immunotherapy | 9.9 | 91 | Citations (PDF) |
| 361 | DNA electrotransfer: its principles and an updated review of its therapeutic applications | 3.5 | 260 | Citations (PDF) |
| 362 | Exosome-based immunotherapy | 4.6 | 129 | Citations (PDF) |
| 363 | Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors | 4.0 | 64 | Citations (PDF) |
| 364 | A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer | 2.6 | 192 | Citations (PDF) |
| 365 | Malignant effusions and immunogenic tumour-derived exosomes | 62.1 | 898 | Citations (PDF) |
| 366 | Magnetic minerals as indicators of major environmental change in holocene black sea sediments: preliminary results | 3.9 | 21 | Citations (PDF) |
| 367 | Tumor-derived exosomes: a new source of tumor rejection antigens | 3.1 | 196 | Citations (PDF) |
| 368 | Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy | 4.0 | 128 | Citations (PDF) |
| 369 | Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO* analysis of prognostic factors | 5.5 | 63 | Citations (PDF) |
| 370 | Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non–small cell lung cancer | 2.6 | 126 | Citations (PDF) |
| 371 | Persistence of viable tumor cells after radiation and chemotherapy for stage IIIB non[ndash ]small cell lung cancer: An early marker of treatment failure | 2.6 | 6 | Citations (PDF) |
| 372 | Peritoneal Carcinomatosis in Germ-Cell Tumor | 1.3 | 4 | Citations (PDF) |
| 373 | The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients | 4.9 | 235 | Citations (PDF) |
| 374 | Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons | 5.3 | 2 | Citations (PDF) |
| 375 | DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer | 6.8 | 0 | Citations (PDF) |
| 376 | SparseXMIL: Leveraging sparse convolutions for context-aware and memory-efficient classification of whole slide images in digital pathology | 10.6 | 0 | Citations (PDF) |
| 377 | Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts | 2.6 | 2 | Citations (PDF) |
